Epithelial alarmins: a new target to treat chronic respiratory diseases

Denislava Nedeva,Krzysztof Kowal,Stefan Mihaicuta,Guillermo Guidos Fogelbach,Paschalis Steiropoulos,Herberto Jose Chong-Neto,Angelica Tiotiu
DOI: https://doi.org/10.1080/17476348.2023.2262920
2023-10-04
Expert Review of Respiratory Medicine
Abstract:Introduction In response to injury, epithelial cells release alarmins including thymic stromal lymphopoietin (TSLP), high mobility group-box-1 (HMGB1), interleukin (IL)-33 and −25 that can initiate innate immune responses. These alarmins are recognized as activators of T2-immune responses characteristic for asthma, but recent evidence highlighted their role in non-T2 inflammation, airway remodeling, and pulmonary fibrosis making them an attractive therapeutic target for chronic respiratory diseases (CRD).
respiratory system
What problem does this paper attempt to address?